• Ipsen's latest R&D alliance brings novel T cell-activating drugs for cancer

    15 days ago - By MedCity News

    Ipsen has been an active dealmaker lately, and it just struck another one that takes the pharmaceutical company into a new area of drug research. The Paris-based company is collaborating with Marengo Therapeutics on the development of two drugs that selectively activate T cells to fight cancer.
    Read more ...

     

  • Aiming to bring drug combos into earlier lines of cancer therapy, IDRx lands $122M

    Aiming to bring drug combos into earlier lines of cancer therapy, IDRx lands $122M

    15 days ago - By MedCity News

    Taking inspiration from the success of drug cocktails that halt viral infections, startup IDRx aims to develop cancer drug combinations that stop tumor escape. The company, founded by serial entrepreneur Alexis Borisy, has set gastrointestinal stromal tumor as its first disease target.
    Read more ...